Seven (21.9%) patients discontinued apatinib, of whom one patient discontinued due to life-threatening tumor bleeding during the second cycle of neoadjuvant therapy and transferred to emergency surgery, one was assessed as disease progression after two cycles, one discontinued due to uncontrolled hypertension, two discontinued due to repeated grade 3 or 4 thrombocytopenia, and two discontinued due to prolonged elevation of ALT and/or AST. The gene discussed is GPT; the disease is Hypertension.